Mentioned 6 times on 1 show. Most recently heard 14/09/2026.
Every quote is verbatim and timestamped, and checked before it appears. Sponsor reads are left out. How we check
“events by LDL lowering because it lowers LDL also. That was actually post-tricetrapib. So tricetrapib was the Pfizer CTP inhibitor. Everyone was rushing to get a CTP inhibitor because it raised HDL 50%, 75%. We thought we'd have the cure for heart disease. Every 1% increase in HDL in these other trials lowered risk by 3%.”
“Okay. So then the Roche compound comes along. What was the story with that trial? So it's a weak CTP inhibitor, and they even call it a CTP modulator, a very safe drug. And it raised HDL 30%, maybe 40% in some trials. So not much weaker HDL raising effect, no LDL effect.”
“have that effect. CTP inhibitors are one of them. Niacin, you know, HDL drugs of a different type. So triglyceride lowering automatically.”
“And of course, these were all... They were all initially investigated because of the potential to create higher HDL cholesterol. And now we certainly know that HDL cholesterol is not the HDL biomarker of interest, and people were being fooled into thinking that would have benefit.”
“So what I told you is true, especially with the most powerful CETP inhibitors. They reduce small HDLP by 10% or 20%. If you ignore what's going on in HDL and you only look at what's happening with ApoB and LDL, you think obicetrapib is a no-brainer, it's going to be positive.”
“Yes, basically, CETP inhibitors of which OB-Cetropib is the latest have been investigated to see what they do to atherosclerotic heart disease and LP-little A and maybe brain functioners.”